---
title: "Moderna Stock Is Trading Higher Monday: What's Going On?"
description: "Moderna, Inc. (MRNA) shares rose 2.73% to $27.28 after the FDA approved its new COVID-19 vaccine, mNEXSPIKE, for seniors and at-risk individuals. The vaccine demonstrated higher efficacy and a similar"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242814430.md"
published_at: "2025-06-02T17:20:19.000Z"
---

# Moderna Stock Is Trading Higher Monday: What's Going On?

> Moderna, Inc. (MRNA) shares rose 2.73% to $27.28 after the FDA approved its new COVID-19 vaccine, mNEXSPIKE, for seniors and at-risk individuals. The vaccine demonstrated higher efficacy and a similar safety profile compared to the original vaccine in Phase 3 trials. CEO Stéphane Bancel emphasized the importance of this approval in combating COVID-19, which remains a significant public health threat. mNEXSPIKE is expected to be available for eligible populations in the U.S. by the 2025-2026 respiratory virus season, with global regulatory reviews ongoing.

**Moderna, Inc.** MRNA shares are trading higher Monday after the company announced its new COVID-19 vaccine secured clearance from the U.S. Food and Drug Administration (FDA) for seniors and at-risk individuals.

**What To Know:** In a Phase 3 clinical trial, the new vaccine, mNEXSPIKE, showed a higher vaccine efficacy as well as a similar safety profile compared to the company’s original COVID-19 vaccine.

“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said **Stéphane Bancel**, CEO of Moderna.

“COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA’s timely review and thank the entire Moderna team for their hard work and continued commitment to public health.”

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season. The new vaccine is under review with regulators in multiple markets around the world.

**MRNA Price Action:** At the time of writing, Moderna stock is trading 2.73% higher at $27.28, according to data from Benzinga Pro.

*Image: Shutterstock.*

### Related Stocks

- [MRNA.US - Moderna](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Moderna 与墨西哥政府签署了为期五年的供应和制造协议 | Moderna Inc. 与墨西哥政府及当地合作伙伴签署了一项为期五年的协议，供应其呼吸道疫苗组合并进行 COVID-19 疫苗的国内生产技术转让。这项合作与墨西哥的健康主权倡议相一致，并包括当地的临床研究。该协议是在 Moderna 的  | [Link](https://longbridge.com/en/news/275453337.md) |
| 期权热点｜周二 MRNA 大涨 17%，部分看涨期权飙升 878% | 美东时间 01 月 13 日，Moderna 期权总成交 122203 张，看涨期权占比 59%，看跌期权占比 40%。 | [Link](https://longbridge.com/en/news/272496497.md) |
| 每千次展示 60 美元！OpenAI 用高价拉开 “AI 广告” 大幕 | 为应对 AI 巨额开支，OpenAI 正式测试广告，CPM60 美元起步、最低投入 20 万美元，定位高端渠道，直接挑战谷歌万亿美元市场，WPP 等顶级代理已率先合作。但转型风险并存：需平衡用户信任，承诺不用私聊数据；对手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) |
| 奔驰中国换帅，告别 “段建军时代” | 首位本土高管身退。 | [Link](https://longbridge.com/en/news/275976978.md) |
| 美股盘中速递：莫德纳股价涨 11.79%，mRNA 疫苗临床数据激发市场信心！ | Moderna 涨 11.79%；艾伯维涨 0.50%，成交额达到 12.97 亿美元；安进涨 2.55%，成交额达到 6.2 亿美元；福泰制药涨 3.77%，成交额达到 4.86 亿美元；吉利德科学涨 2.66%，市值达到 1581 亿美 | [Link](https://longbridge.com/en/news/273270254.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
